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Pulmonary vein isolation (PVI) was the main strategy for catheter ablation of atrial ﬁbrillation (AF) until
a remarkable report was published by Nademanee et al. in 2004. The ablation targeting complex
fractionated atrial electrograms (CFAE) achieved not only a high rate of AF termination but also
excellent outcomes in both paroxysmal and persistent AF without isolating pulmonary veins. AF is
thought to be caused by random or spiral reentry, as the ﬁxed circuit to maintain AF may not exist,
although the CFAE-guided ablation strategy is based on the theory that AF is not entirely random. CFAEs
play an important role in identifying AF substrates, and have temporal and spatial stability, thus
representing desirable targets for AF ablation; however, CFAE-guided ablation has not been fully
replicated by others. In reports showing that CFAE ablation did not yield a good outcome either alone or
combined with PVI, the AF termination rates were extremely low. Although AF termination is not
mandatory in CFAE-ablation, terminating AF in the majority of patients appears to be necessary to yield
good outcomes; therefore, this review will discuss AF ablation guided by CFAE with or without PVI,
with particular emphasis given to practical aspects of achieving AF termination.
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Atrial ﬁbrillation (AF) is a common cardiac arrhythmia that
becomes more prevalent with age [1] and is associated with an
increased long-term risk of stroke, heart failure, and all-cause
mortality [2]. Since Einthoven recorded the electrograms in 1906
[3], AF has widely been recognized as ‘‘absolute arrhythmia’’,
although the mechanisms of AF are still uncertain. The activation
patterns that underlie the irregular electrical activity that occurs
during AF have traditionally been described as disorganized or
random [4–10]. The mechanisms of AF are considered to be
random or spiral reentry without ﬁxed circuits, as observed in
the accessory pathways of Wolff–Parkinson–White (WPW) syn-
drome. Thus, the target of AF ablation is not the substrate, but
instead the trigger in general, although the ablation target of
accessory pathways is typically not the trigger. Therefore, in
patients with long-standing AF in which the substrate is suppo-
sedly more important than the trigger, ‘‘rate control’’ is more
common than ‘‘rhythm control.’’ However, studies based predo-
minantly on statistical methods have provided evidence that AF is
not entirely random [11,12], and Madapati and colleagues
reported that stable microreentrant sources were the most likely
underlying mechanism of AF in a sheep model [13]. Thus, the
mechanisms of AF are still controversial, particularly in humans.
After the Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) [14] and Resynchronization–Deﬁbrillation
for Ambulatory Heart Failure Trial (RAFT) [15] demonstrated that
the strategy of maintaining sinus rhythm with antiarrhythmic
drugs was not better than that of rate control in conjunction with
anticoagulation, the development of catheter ablation emerged as
an alternative approach for treating AF patients without antiar-
rhythmic drugs. Shortly after Swartz et al. introduced the catheter-
based Maze procedure [16], Haissaguerre and colleagues published
a paper revealing that the pulmonary veins (PVs) are an important
source of triggering foci for paroxysmal AF [17]. The initial ablative
approach was to focally ablate the culprit PV identiﬁed as the
triggering site initiating AF [17,18], and electrophysiologists began
to isolate the electrical connections of all 4 veins from the left atrial
(LA) muscle. To avoid PV stenosis and to attempt to include more
AF substrate in the isolated areas, numerous investigators now
perform PV isolation (PVI) further away from the PV ostia, thereby
creating wider areas of LA ablation.
A recent consensus of world-renowned experts in AF ablation
stated that PVI is a cornerstone of catheter ablation of the AF, and
most laboratories perform PVI as the primary approach for
patients with paroxysmal AF [19]. Its success rate in the parox-
ysmal AF subset ranges from 38% to 70% after a single procedure
and 65% to 90% after repeated procedures. However, PVI alone is
not effective for treating patients with persistent AF [19]. In these
patients, additional linear lesions are intended to eliminate
additional arrhythmogenic substrate and to prevent large atrial
reentrant circuits that are potentially involved in perpetuation
of AF; complete linear lesions have been shown to improve
outcomes [20]. PVI in addition to ablation at the roof and mitral
isthmus achieved sinus rhythm in 69% of patients with persistentAF compared with only 20% of patients who underwent PVI alone
[21]. Linear ablation in addition to PVI was demonstrated to be
effective in preventing atrial tachycardia after circumferential
PV ablation for paroxysmal AF [22], whereas macroreentrant
arrhythmias that occur during follow-up are frequently related
to gaps in previous linear lesions [23,24].
The ideal approach to identify target sites of AF ablation would
be to ﬁnd substrates that perpetuate the arrhythmia. In the past,
it was believed that AF substrates could not be mapped since
reentrant circuits underlying the substrate are random and not
amenable to point-to-point or endocardial mapping. However,
recent observational studies by Nademanee et al. have demon-
strated that substrates serving as ‘‘AF perpetuators’’ can be
identiﬁed by searching for areas that have complex fractionated
atrial electrograms (CFAEs) [25,26]. During sustained AF, CFAEs
are often recorded in speciﬁc areas of the atria, and exhibit
temporal and spatial stability [25,27]. By ablating areas that have
persistent CFAE recording, these studies showed that AF was
terminated in over 85% of patients, and the procedure yielded a
very good long-term outcome in both paroxysmal and chronic AF
patients [25,26]. Although 8 years have passed since the ﬁrst
report was published, CFAE-guided ablation has not been fully
understood until now. An excellent review of CFAE-ablation was
previously published by Nademanee et al. [28], thus this review
will focus on the practical aspects of CFAE-ablation combined
with or without PVI and will describe some representative cases
to provide guidance for CFAE-ablation.
1.1. Electrogram-guided ablation: keys to ﬁnding areas to be ablated
CFAEs are deﬁned as low-voltage atrial electrograms (range,
0.04–0.25 mV) that have fractionated electrograms composed of
2 deﬂections or more, and/or have a perturbation of the baseline
with continuous deﬂection of a prolonged activation complex.
CFAEs sometimes have a very short cycle length (r120 ms) with
or without multiple potential; however, when compared to the
rest of the atria, this site has the shortest cycle length.
The deﬁnition of CFAE is simple, but the characteristics of the
electrograms may not be well understood. CFAE shows temporal
and spatial stability, thus the recognition of CFAE is an important
key to terminating AF. The appearance of electrograms may be
altered when AF is organized or changed to atrial tachycardia (AT)
or ﬂutter (AFL). Interestingly, some patients had both AF and
AT/AFL, which switched patterns spontaneously before ablation.
When the catheter left the areas of CFAE, the appearance of CFAE
also changed from a continuous to an organized pattern. These
events also occurred after certain amounts of radiofrequency (RF)
were applied to the areas of CFAE in many AF patients. Fig. 1
shows some representative electrograms of CFAE before ablation
and before the last RF applications to terminate AF. Typical
continuous CFAEs are easily recognized, although when AF is
organized or changed to AT/AFL, CFAEs could also be organized. In
addition, small electrograms around areas that were previously
ablated are also important. CFAEs exist not as sparse points, but
are found in some dense areas. After burning the CFAE areas, the
Fig. 1. Complex Fractionated Atrial Electrograms (CFAEs). The ablation catheter
(ABL d) is used to map and ablate the CFAE. Three representative electrograms
were cited from Ref. [38]: (A) typical electrogram of continuous CFAE. This is the
ﬁrst target of CFAE-ablation. (B) Typical electrogram of organized fractionated
potentials. It is found in patients whose AF is organized or changed to atrial
tachycardia or ﬂutter. The potentials are typically observed in areas previously
ablated targeting continuous CFAE. After radiofrequency (RF) applications to this
area, this arrhythmia was terminated. (C) Typical electrogram of very low voltage
fractionated potentials, with the highest amplitude of the potentials o0.06 mV;
this was also identiﬁed at the previously ablated areas. After RF applications to
this area, this arrhythmia was terminated. CS¼coronary sinus.
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less fractionated, and/or more organized. There may be concern
regarding how we approach ﬁnding residual CFAE sites. Since
CFAEs have temporal and spatial stability, we tried to identify
residual CFAE sites around the tagged and/or previously ablated
areas, occasionally with nifekalant to highlight the residual CFAEs
with increasing AF cycle length. Nifekalant may terminate AF byitself; however, we conﬁrmed that the outcome was not affected
by using nifekalant.
Re-maps after some RF applications are not necessary to
identify residual CFAE sites, except when AF changes to stable
AT/AFL. We occasionally try to ﬁnd residual CFAE sites by using
activation maps to terminate the AT/AFL, although liner ablations
are not attempted with this approach. Creating precise CFAE maps
would be particularly useful in areas in which CFAEs are com-
monly found before ablation, although CFAEs exist not as sparse
points, but in some dense areas, thus creating precise maps in
entire LA is not mandatory.
1.2. Regional distribution of CFAE
Even when some of the CFAE areas are not detected during
CFAE mapping, knowledge of speciﬁc areas that have predilection
to be sites of CFAE may also be helpful to achieve AF termination.
The following key areas have demonstrated a predominance of
CFAE [25,26]: (1) the septal wall anterior to the right superior and
inferior PVs, (2) the anterior wall medial to the LA appendage,
(3) the posterosuperior wall medial to the left superior PV, (4) the
area between the LA appendage and left superior PV, (5) the
proximal coronary sinus (CS) and CS ostium, and (6) the superior
vena cava (SVC)-right atrial (RA) junction to RA septal wall, which
is counterpart of (1). Typically, patients with persistent AF have
greater numbers and locations of sites with CFAE than those with
paroxysmal AF [25].
1.3. Electrophysiologic mechanisms underlying CFAEs
The most prominent theory underlying the occurrence of CFAE
involves the complex interplay of the intrinsic cardiac nervous
system on atrial tissues. The cardiac ganglionic plexi (GP) are a
collection of autonomic nervous tissues with afferent and efferent
sympathetic and parasympathetic ﬁbers [29–32]. Fig. 2A shows
the region of 6 major GP. Lockwood et al. reported that the
distribution of CFAE is similar to that of GP in paroxysmal AF
patients compared to persistent AF patients (Fig. 2B). Fig. 2C–E
show the examples of CARTO maps. The ablated areas are similar
in the areas of GP in this paroxysmal patient, which is not
observed in the persistent patient. We speculate that CFAE may
represent physiologically sick atrial cells; while the depolariza-
tion of the cells is not homogeneous, the electrogram may be
fractionated. Thus, atrial stretch may be a reason for the occur-
rence of CFAE, and atrial cardiomyopathy caused by virus infec-
tion may be another reason. We reported that toll-like receptor 2
(TLR2), a biomarker of inﬂammation, was elevated in patients
with non-valvular AF relative to those without AF [33].2. Methods
We described our strategies for ablating AF in previous reports
[34–36]. Therefore, we will discuss our methods for CFAE abla-
tion, including CFAE-ablation combined with PVI, below.
2.1. Procedural details of CFAE ablation
2.1.1. Solely guided by CFAE
After an esophageal temperature probe (Fiab, Vicchio, Florence,
Italy) was inserted nasally, 3 right femoral punctures are
performed for the procedure; an 8.5F SL0 (SJM, Irvine, CA, USA)
for a Navistar THERMOCOOL (Biosense-Webster, Diamond Bar, LA,
USA), an 11F custom-made long sheath (Zeon Medical, Tokyo,
Japan) for a 10F SOUNDSTAR (Biosense Webster), and a 7F short
sheath for a decapolar (BARD, Murray Hill, NJ, USA). The decapolar
Fig. 2. (A) Six cardiac ganglionic plexi (GP) are located on or near the left and right atria and have been shown to inﬂuence the initiation and perpetuation of atrial
ﬁbrillation (AF): superior left atrial GP, posterolateral left atrial GP, posteromedial left atrial GP, left anterior descending GP, posterior right atrial GP, and superior right
atrial GP. AP¼anteroposterior; PA¼posteroanterior; LAA¼ left atrial appendage; RAA¼right atrial appendage; CS¼coronary sinus; LOM¼ ligament of Marshall;
SVC¼superior vena cava; LSPV¼ left superior pulmonary vein; LIPV¼ left inferior pulmonary vein; RSPV¼right superior pulmonary vein; RIPV¼right inferior pulmonary
vein (adapted from Ref. [29,30]). (B) The most common locations of CFAE are identiﬁed (darkest shading) on a grid representing the regions of the right and left atria
(adapted from Ref. [31]). LA¼ left atrium; LAA¼ left atrial appendage; RA¼right atrium; CS¼coronary sinus; FO¼fossa ovalis; LSPV¼ left superior pulmonary vein;
LIPV¼ left inferior pulmonary vein; RSPV¼right superior pulmonary vein; RIPV¼right inferior pulmonary vein. (C) and (D) Example of anteroposterior (C) and
posteroanterior (D) views of electroanatomical maps from a patient who had paroxysmal AF. In this patient, the ablated areas are similar to the areas of GP. (E) Example of
anteroposterior (left panel) and posteroanterior (right panel) views of electroanatomical maps from a patient who had 1-year persistent AF. In this patient, the ablated
areas are not similar to the areas of GP. Ablated areas occur more frequently in anterior and septal LA relative to posterior LA.
N. Oketani et al. / Journal of Arrhythmia 28 (2012) 311–323314catheter (BARD) is cannulated in the CS for reference and pacing.
A single transseptal puncture under ﬂuoroscopic and intracardiac
echo (SOUNDSTAR or AcuNav, Biosense-Webster) guidance is used to
access the LA. Patients who are not in AF at the onset of the procedure
undergo an aggressive induction protocol utilizing burst pacing in
the CS at a lower limit of 1:1 capture or L150ms with additional
intravenous isoproterenol (dose, 0.005–0.01mg kg1 min1), as
required. We create maps with a fast anatomical map by CARTO3
with a CARTO-Merge of the LA, CS, and occasionally the RA.
CFAE maps are created during AF (either spontaneous or by
induction) as follows; ﬁrst, a CS map is created, and when areas of
CFAE are detected, pink dots are tagged in the areas. Second, after
creating the CS map, the anatomical structure of the LA is assumed
from the 3-dimensional computed tomography (3D-CT) using
CARTO-Merge, thus the LA map is created easily and safely with
minimum use of ﬂuoroscopy. Pink dots are also tagged in LA. We
identify locations with stable fractionated electrograms, and tag
the maps with pink dots in these areas to create landmarks for
CFAE-ablation. Areas with ﬂeeting CFAE are not sought as a
primary target. The spatial and temporal stability of CFAE allows
for the precise localization of these electrograms, and these highlyreliable maps allow for minimal use of ﬂuoroscopy. Our mean
ﬂuoroscopic time after CARTO3 was available by 4 operators was
15 min, while occasionally including PVI and/or coronary angio-
graphy. Initial CS and LA mapping is the most important step to
properly perform CFAE-ablation.
A Pruka device (SJM) is used as a recording system in our
institution. Increasing the gain of the ablation catheter to the
maximum is useful to recognize CFAEs with the Pruka. The
default range is appropriate with the EP-Workmate system (EP
Medsystems, West Berlin, NJ, USA). Recently, a customized soft-
ware package was developed to assist in the process of mapping
(CFAE software module, CARTO, Biosense-Webster) [37]. Shortest
complex interval (SCI) maps are typically used in our procedures;
information from these variables is projected onto a 3-D electro-
anatomic shell, according to a color-coded scale. This allows for
targeting of areas of signiﬁcant CFAE combined with the pink tags.
We use an open-irrigation 3.5-mm-tip ablation catheter with a
bi-directional large or extra large curve (THERMOCOOL DF or FJ,
Biosense-Webster) irrigating at 30 ml/min during lesion creation.
Power settings are set at a maximum of 40 W throughout the
atria with the temperature limiter of 43 1C, with the exception of
Fig. 3. Example of CARTO voltage maps and intracardiac electrocardiograms of a patient with persistent atrial ﬁbrillation (AF) (adapted from Ref. [34]). A 46-year-old
patient with persistent AF of longer than 1 months’ duration. AF could not be converted to sinus rhythm without cardioversion: (a) the anteroposterior (AP) view of the
CARTO voltage map of the left atrium (LA) and coronary sinus (CS). Pink dots represent the points in the intracardiac electrogram that showed complex fractionated atrial
electrogram (CFAE) when creating the voltage map before ablation. Blue dots represent the area of the mitral valve annulus. Yellow dots represent the termination point of
atrial tachycardia (AT). (b) The posteroanterior (PA) view of the CARTO voltage map. (c) The right upper panel shows the AP view of the CARTO map mesh image of the LA
and CS. The left upper panel shows the intracardiac electrocardiogram of the bottom of the right superior pulmonary vein (RSPV), which is an example of CFAE. In this
patient, AF was changed to AT (cycle length of 356 ms). Our targets were still the fractionated potentials after AF changed to AT, although the electrograms were also
‘‘organized’’ (left bottom panel). Bottom panels show the intracardiac electrocardiograms before and after the AT termination caused by radiofrequency (RF) application to
the roof of the LA (yellow dot, arrow); sinus rhythm was maintained after this RF application. The RF point was located in the same area in which we ablated the AF. The
linear ablations were not made to attempt to terminate AT. The primary ablated areas included: (1) lower septum, (2) ridge of the LA appendage, (3) LA roof, (4) proximal
CS, (5) posterior aspect of the left PVs, and (6) bottom of LA posterior wall. RF duration was 137 min.
N. Oketani et al. / Journal of Arrhythmia 28 (2012) 311–323 315the posterior wall closed to esophagus and CS (15 W). RF duration
is usually 40 s.
After we attempt to eliminate all of the pink-tagged areas in LA,
we search for the CFAE areas in the CS and its ostium, septal
isthmus, lateral isthmus, SVC, and right septal wall. One of the most
important aspects of CFAE-ablation is to revisit areas that were
initially ablated to ensure that there is no residual electrical activity.
If the patient remains in AF despite elimination of all visible CFAEs,
intravenous nifekalant (dose, 0.3 mg/kg for over 10 min; repeat
twice at the maximum) is used to increase the cycle length of the
arrhythmia in ‘‘non-driver’’ atrial tissue and thereby highlight the
remaining areas of greatest impact for ablation.
Often during CFAE-targeted AF ablation, the arrhythmia
evolves into an organized AF or AT/AFL (Fig. 3). Using the CS
catheter as a reference, the AT/AFL is subsequently mapped and
ablated. Most often the sites of the AT/AFL origin are found at thesame locations as the CFAE, which were targeted during the initial
part of the AF ablation procedure. The endpoints that we employ
are either (1) conversion to sinus rhythm (and if the presenting
rhythm was paroxysmal AF, it must not be re-inducible) or
(2) elimination of all CFAEs.
Occasionally, a patient will remain in AF or AT/AFL after an
extensive ablation with elimination all CFAEs, despite the use of
nifekalant. In this small group of patients, an internal cardiover-
sion is required. If the AF is not terminated or re-induced
spontaneously (which is extremely rare), we typically repeat the
search for residual CFAE areas to maintain sinus rhythm.
The LA sheath and the Navistar catheters are sometimes pulled
out from LA to RA (either intentionally or accidentally) after
creating the CFAE maps. For the occasions in which it is difﬁcult to
catheterize the LA, we create a ‘‘virtual LA sheath image’’ (Fig. 4).
After septal puncture and the SCI map of CS are created, the SL0 is
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in the RA to monitor for pericardial effusion.2.1.2. Combined with PVI
Most laboratories perform PVI as the primary approach for AF
patients. We also utilize PVI in some cases; we complete the
isolation in the patients who have a history of PVI, and we are
currently involved in an ongoing study to compare the efﬁcacy of
performing AF ablation solely guided by CFAE to that of perform-
ing PVI prior to CFAE ablation (PVIþCFAE, Fig. 5). There are some
notable differences between the methodology for PVIþCFAE and
that of ablation solely guided by CFAE. When we perform PVI
combined with CFAE ablation, an additional SL0 catheter is used
instead of an 11F long sheath. An 8F AcuNav (Biosense Webster) isFig. 5. A case of paroxysmal atrial ﬁbrillation (AF). Pulmonary vein isolation (PVI, gre
times (yellow dots) only by PVI. In such cases, additional CFAE ablation alone was nee
Fig. 4. Example of the ‘‘virtual left atrial (LA) sheath image.’’ This type of imaging
is useful when the LA sheath and catheter are intentionally or accidentally pulled
out from the LA to the right atrium need to be replaced. We could easily ﬁnd the
correct insertion hole by referring to this image.used instead of a SOUNDSTAR to perform the septal puncture.
After the septal puncture, CFAE maps are created during AF in by
the same approach as described for ablation solely guided by
CFAE. PVI is performed ipsilaterally without circular catheters by
CARTO-Merge during AF (spontaneous or by induction) to conﬁrm
whether PVI terminates AF. When AF is not terminated by PVI, AF
is terminated by internal cardioversion. When sinus rhythm is
maintained after cardioversion, we insert another SL0 sheath into
the LA via the same hole. Single Lasso (Biosense Webster) or
Optima (SJM) is used to complete the isolation. After the isolation
is complete and when AF is still inducible, CFAE ablation is
continued until AF is not inducible. Of note, sinus rhythm could
not be maintained after PVI in some cases, particularly in patients
with persistent AF, thus PVI is completed after CFAE ablation in
such cases.2.2. Useful tools for CFAE ablation
There are some useful tools for CFAE ablation; we will discuss
the beneﬁts of each tool below.2.2.1. CARTO3 and CARTO-Merge
CARTO3 with CARTO-Merge allows us to perform AF ablation
with a relatively short ﬂuoroscopic time. The mean ﬂuoroscopic
time after CARTO3 became available in our institute (July 2011–
February 2012) was 10 min with ablation solely guided by CFAE
and 17 min when combined with PVI, by 4 operators.
CARTO-Merge is not required to perform CFAE ablation;
however, we use it for almost all of our cases except for patients
with chronic kidney disease or those who are allergic to the
contrast agent. The beneﬁts of CARTO-Merge are as follows:
(1) the map of the entire LA is created safely after the CS map is
created and loosely merged. The incidence of hemocardium
during procedures using CARTO-Merge was lower than that of
procedures without CARTO-Merge in our institute, thus the risk of
hemocardium may be reduced by using CARTO-Merge. (2) We are
able to understand the precise anatomy of both atria and the CS
with CARTO-Merge. PV angiography for PVI may not be necessary
with CARTO-Merge. Importantly, the merged images should
match the real-time maps perfectly.en dots) was combined with CFAE ablation (red dots). AF was terminated several
ded in several points.
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CARTOSOUND is now available in Japan. The beneﬁts of
CARTOSOUND are as follows: (1) contrast is not needed to
perform transseptal puncture, since microbubbles are detected
when normal saline is injected (Fig. 6A). (2) The images of
CARTOSOUND are of high enough quality to aid in detecting left
atrial appendage (LAA) thrombi. We need to abort AF ablation if
LAA thrombi are detected, thus transesophageal echocardiogra-
phy (TEE) in low risk patients may be reduced by using CARTO-
SOUND. (3) CARTOSOUND aids in the detection of the esophagus
(Fig. 6B and C). The temperature probe in the esophagus detected
by CARTO3 is routinely used in our institute, and CARTOSOUNDFig. 6. (A) Trans-septal puncture; image of tenting and microbubbles caused by injec
(B) Posteroanterior view of the CARTO map. The position of the esophagus was estim
esophageal map constructed by CARTOSOUND. (C) Esophagus detected by CARTOSOUN
is also detected by CARTOSOUND when the probe is not in the esophagus.also detects the real-time position of the esophagus. The position
of the esophagus is not always stable during the session, thus we
need to monitor the real-time position of the esophagus to ablate
the posterior wall of the LA. (4) CARTOSOUND allows for the
detection of pericardial effusion. We leave CARTOSOUND in the
RA to monitor for pericardial effusion during the procedure.
Pericardial effusion is typically detected before the arterial
pressure decreases.
In other procedures, we use CARTOSOUND to calculate the LAA
ﬂow speed. We suggest that it is useful to perform the CARTO-Merge
with CARTOSOUND, although we were already accustomed to creat-
ing whole LA maps without CARTOSOUND until it became available.ted saline (left panel). Contrast is not required for septal puncture (right panel).
ated by merged computed tomography (CT) image, temperature probe, and the
D. When a temperature probe is in esophagus, it is clearly detected; the esophagus
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Although esophageal temperature monitoring may not always
guarantee that esophageal injury is avoided, we reported the
correlation between the distance from the ablation catheter to the
esophageal images and esophageal temperature rise [36]. The
esophageal probe is visualized by CARTO3 and allows us to
measure the esophageal temperature (Figs. 6B, C, and 7). The
position of the probe is adjusted to the distance closest to the
ablation catheter without ﬂuoroscopic guidance.3. Results
3.1. AF termination by catheter ablation guided by CFAE in the
Paciﬁc Rim, Dr. Nademanee’s Institute
We analyzed our subsequent experiences with 616 patients (206
with paroxysmal AF, 410 with persistent AF) who had undergone
CFAE-guided AF ablation from January 2006 to December 2007 in
the Paciﬁc Rim [38]. In this group, we were able to terminate AF to
sinus rhythm during ablation of CFAE target sites in 203/206 (99%)
of paroxysmal AF patients and 328/410 (80%) of persistent AF
patients, occasionally with ibutilide. The remaining patientsFig. 7. (A) The position of the merged esophageal image was similar to that of the rea
image was markedly different from that of the real-time esophageal probe in this patirequired external cardioversion to restore and maintain sinus
rhythm. The common areas of CFAE were located at the anterior
aspect of the right PV antrums, the posterior aspect of the left PV
antrums, the ridge of the LA appendage, the proximal CS, and the
posterior septum of the RA (Fig. 8). We also studied 410 consecutive
AF patients who had undergone CFAE-guided AF ablation in their
ﬁrst session from January 2005 to June 2007 (mean age: 63 years)
[39]. We followed these patients for at least 12 months (mean,
2878 months), and a second session was required (redo group) for
38% of patients with paroxysmal AF and 47% of patients with
persistent AF. Age, RF time, and whether ibutilide or cardioversion
was required were not good predictors for patients requiring second
procedures. However, LA volume (p¼0.047) or body mass index
(BMI; 0.016) were good predictors. The patients’ LA volume esti-
mated with CARTO was 143 cm3 in the redo group, and 130 cm3 in
the non-redo group. Thus, we concluded that AF ablation should be
performed earlier when the LA volume is still relatively small.
3.2. AF termination by catheter ablation guided by CFAE in our institute
We analyzed all of our subsequent experiences with 340
patients (187 with paroxysmal AF, 153 with persistent AF) who
had undergone CFAE-guided AF ablation from September 2008 tol-time esophageal probe in this patient. (B) The position of the merged esophagus
ent.
Fig. 8. The common areas of atrial ﬁbrillation (AF) termination. The numbers
represent the termination rate in the each region (adapted from Ref. [38]; more
than 5% are cited): (A) the grid of the posterior and anterior walls of the left atria
(LA). (B) The grid of the lateral and septal walls of the LA. (C) The grid of the septal
wall of the right atria and the coronary sinus. We deﬁned the cavo-tricuspid
isthmus, superior vena cava-right atria junction, and the low lateral right atria as
1 region of each area.
Table 1
Comparison of termination rate, RF time, procedure time, and ﬂuoroscopic time in
paroxysmal and Persistent AF with or without pulmonary vein isolation per-
formed from September 2008 to February 2012.
Paroxysmal AF (n¼187) Persistent AF (n¼153)
Termination rate 185 (98%) 115 (78%)
RF time (min) 75733 84734
Procedure time (min) 217768 233773
Fluoroscopic time (min) 24718 24716
AF¼atrial ﬁbrillation; RF¼radiofrequency.
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we were able to terminate AF to sinus rhythm during ablation of
CFAE target sites with or without PVI in 98% of paroxysmal
AF patients and 78% of persistent AF patients, occasionally
with nifekalant to highlight the residual CFAE sites instead of
ibutilide.
The mean RF time, procedure time, and ﬂuoroscopic time
including procedures occasionally performed with PVI and/or
coronary angiography (CAG) are shown in Table 1.
3.3. AF termination by PVI
Although AF termination may not require PVI, PVI-based
strategies for AF termination were reported to yield excellent
outcomes [23]. Fig. 5 shows a patient who underwent CFAE
ablation combined with PVI. When PVI is combined with CFAE-
ablation in our institute, we perform PVI prior to CFAE ablation
during AF (spontaneous or by induction) to determine how
effective the PVI procedure is for AF termination. In the patient
described in Fig. 5, AF was terminated repeatedly during the PVI,
and the number of additional RF applications needed to eliminate
residual CFAE areas, with the exception of isolated areas, was
small. PVI terminated AF in 43% (13/30) of proximal AF patients
and 11% (2/19) of persistent (AF lasting o1 year) patients among
those without histories of AF ablation. There were only 2 patientswith paroxysmal AF were not inducible after PVI. PVI is effective
in majority of paroxysmal AF patients, although the efﬁcacy of PVI
is limited in paroxysmal AF patients among those that are elderly,
have hypertrophic cardiomyopathy, large LA volume, persistent
left SVC (PLSVC), and/or a history of maze procedure. We will
describe patients with these conditions that underwent CFAE
ablation in a subsequent section.
3.4. Relationship between clinical outcomes and unintentional PVI
during substrate ablation of AF guided solely by CFAE mapping
We reported a study that evaluated the effectiveness of AF
ablation guided solely by targeting CFAE areas, and sought to
determine whether its clinical efﬁcacy had any relationship with
unintentionally isolating the PV [34]. We studied 100 consecutive
patients (aged 59711 years; 54 with paroxysmal AF, 35 with
persistent AF, and 11 with long-standing persistent AF), who
underwent CFAE-ablation. PV potential (PVP) was recorded before
and after ablation. After excluding 39 patients in whom sinus
rhythm could not be maintained before ablation by an internal
cardioversion and/or who had a history of PVI(s), PVPs were
analyzed. AF was terminated during ablation in 98% of parox-
ysmal AF patients, 80% of persistent AF patients, and 55% of long-
standing persistent AF patients. Nifekalant (dose, 0.3–0.6 mg/kg)
was administered in 30%, 57%, and 83%, of AF patients, respec-
tively. The common areas of CFAE around the PVs were located
anterior to the right PVs, posterior to the left PVs, and at the ridge
of the. Among 215 PVs in 61 patients (42 with paroxysmal AF, 19
with persistent AF), only 17 PVs (8%) were unintentionally
isolated. The atrial potential to PVP was prolonged (430 ms) in
13% of PVs. After at least 12 months of follow-up (duration, 2375
months), 65% of paroxysmal (11% with the drug) AF patients, 54%
of persistent (37% with the drug) AF patients, and 45% of long-
standing (60% with drug) AF patients were free from atrial
arrhythmia after 1 session. In 26 of 61 (43%) patients, the interval
from the local atrial potential to the PVP was prolonged, or at
least 1 of the 4 PVs was isolated. There was no difference in the
outcome regardless of whether PVP was affected by CFAE-abla-
tion in this study. We concluded that CFAE ablation terminated AF
without isolating PVs in a high percentage of patients, which
yielded good clinical outcomes.
3.5. Complications in CFAE-ablation
In data from the Paciﬁc Rim, among 635 patients at high risk
for stroke who underwent CFAE-guided ablation [40], 5 patients
suffered a cerebrovascular accident (CVA) (0.8%); 2 of the CVAs
occurred 24–48 h after the procedure. Hemopericardium occurred
in 9 patients (1.4%); 1 required a surgical repair, owing to
perforation of the LA. The remaining 6 patients were treated
uneventfully with pericardiocentesis. Thirteen patients developed
vascular complications at the femoral puncture site (7 pseudoa-
neurysms, 2 arteriovenous ﬁstulas, and 4 with severe bleeding
[including 1 patient with retroperitoneal bleeding] at the groin
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high-grade atrioventricular nodal block requiring permanent
pacemaker implantation. Three patients developed transient
pulmonary edema after the procedure, which was resolved with
diuretic therapy. We observed no serious procedure-related late
complications such as esophageal-left atrial ﬁstula or clinical
pulmonary vein stenosis. No procedurally related deaths
occurred; however, 2 patients died within 30 days after the
procedure. One of the patients had a CVA within 48 h of the
procedure and eventually died weeks later. The other patient died
from respiratory failure due to complications of chronic obstruc-
tive pulmonary disease (COPD) and pneumonia.3.6. Incidence of asymptomatic cerebral micro-thromboembolism
after AF ablation guided by CFAE
We previously reported the incidence of cerebral thromboem-
bolism after CFAE ablation with or without PVI [35]. One hundred
consecutive AF patients (50 with paroxysmal AF and 50 with
persistent AF, including 10 long-standing) who underwent CFAE
ablation combined with (n¼41, PVIþCFAE-group) or without
(n¼59, CFAE-group) PVI were studied. CAG was conducted withFig. 9. A case of repetitive atrial ﬁbrillation (AF): (A) the Holter electrocardiogram (ECG
of the CARTO map. We did not ablate the distal portion of the pulmonary veins (PVs
Holter ECGs.AF ablation in 5 cases in which coronary artery stenosis was
suspected on 3D –CT. PVI was performed prior to CFAE ablation
without circular a catheter during AF. After termination of AF,
additional ablation was performed to complete PVI with a circular
catheter. All patients underwent cerebral magnetic resonance
imaging (MRI) including diffusion- and T2-weighted MRI the day
following ablation. New thromboembolism was detected in 7.0%,
and there was no signiﬁcant difference between the 2 strategies
(7.3% in the PVIþCFAE-group vs. 6.8% in the CFAE-group). Con-
gestive heart failure, hypertension, Age475, Diabetes mellitus,
and prior Stroke (CHADS2) score (1.671.0 vs. 0.870.9, po0.05),
LA volume (LAV; 83.8727.1 vs. 67.8721.8, po0.05), and left
ventricular ejection fraction (LVEF, 53.179.2 vs. 65.179.7,
po0.01) were signiﬁcantly different when comparing patients
with or without thromboembolism. In a multivariate analysis,
LVEF (odds ratio [OR], 0.92; 95% conﬁdence interval [CI], 0.84–
0.99; po0.05) and concomitant CAG (OR 18.82; 95% CI, 1.77–
200.00; po0.05) were important predictors of new cerebral
thromboembolism. We concluded that the incidence of cerebral
micro-thromboembolism after CFAE ablation was not greater
than previous reports regarding PVI. Cautious management is
required during AF ablation, particularly in the patients with
low LVEF.) of the case. (B) Anteroposterior view of the CARTO map. (C) Posteroanterior view
), but there were few premature atrial contractions (PACs) observed in repeated
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Ablation is more effective than medical therapy for the treat-
ment of all forms of AF in selected groups of patients [41–43], and
retrospective data are suggestive of a mortality beneﬁt in favor of
AF ablation over conventional treatment [44]. Heart failure and AF
coexist in up to 40% of patients with heart failure, and restoration
of sinus rhythm by catheter ablation of AF in patients with
congestive heart failure has been shown to improve cardiac
function, symptoms, exercise capacity, and quality of life [20].
Nademanee et al. [40] demonstrated that the evidence of stroke
reduction in patients that underwent CFAE-guided catheter abla-
tion and discontinued warfarin after 3 months. The study group
included patients with chronic AF, elderly patients, and those
with LA enlargement, structural heart disease, and heart failure.
With regard to patient selection, it is clear that there are some
patients who derive enough beneﬁt only with PVI, thus additional
extensive ablation may not be necessary, while there are also
some patients who require ablation only in small areas of CFAEFig. 10. Cases of permanent left superior vena cava (PLSVC) with atrial ﬁbrillation (AF):
of a persistent AF case with PLSVC (adapted from Ref. [49]). AF was terminated in the
(LAO, C) view of the CARTO map image of a paroxysmal AF case with PLSVC. We neede
inducible. The left atrium was not ablated in this patient.without PVI. Until now, we could not clearly differentiate these
groups of patients before ablation. In addition, there have been
reports showing that the outcome of PVI alone was limited even
in patients with paroxysmal AF at long-term follow up, and when
PVI is completed in the redo procedure the majority of electro-
physiologists may struggle and be unsure as to how to perform
the next step even in paroxysmal AF without CFAE ablation. Even
though our mean RF time was longer than that of ablation with
PVI only, our stroke rate (including asymptomatic stroke) was
less or equal between procedures, the rate of hemocardium was
comparable, and there were no serious complications such as
LA-esophageal ﬁstula or symptomatic PV stenosis. Thus, we do
not believe that PVI should be the sole ﬁrst-line therapy of AF
ablation, and the majority of AF patients may derive beneﬁts with
CFAE ablation as their ﬁrst-line therapy.
CFAE-guided ablation has not been fully replicated by others.
We hope that this review will be a helpful guide to enable other
institutes to perform CFAE ablation. Our future research interests
include determining a method for combining electrogram-guided(A) Case 1: anteroposterior (AP) and posteroanterior view of the CARTO map image
distal of PLSVC. (B) and (C) Case 2: anteroposterior (B) and left anterior oblique
d to ablate the area of proximal of CS/PLSVC only in this patient, until AF was not
Fig. 11. The CARTO map images of anteroposterior (left panel) and posteroanterior (right panel) views of a patient with 1-month persistent atrial ﬁbrillation (AF) who had
a history of the Maze procedure. The primarily ablated areas included the anterior wall and the septal wall.
N. Oketani et al. / Journal of Arrhythmia 28 (2012) 311–323322and anatomical-guided ablation in order to cure all of the AF
patients with a minimum number procedures and complications.
We would like to not only alleviate the patients’ symptoms, but
also reduce the number of thromboembolic events such as stroke.
Lastly, some representative cases of interest are described below.4. Representative cases of CFAE-ablation
4.1. Repetitive AF
The distal portions of the PVs have been believed to be only
the main foci of premature atrial contractions (PACs) initiating AF.
If so, after the CFAE ablations, quite a few PACs may be concerned.
This case involved a woman with repetitive AF (Fig. 9); she was
quite symptomatic. Unfortunately, repetitive AF was not induced
during ablation even with isoproterenol. Sustained AF was
induced by rapid atrial pacing with isoproterenol, and we per-
formed AF ablation solely guided by CFAE without PVI. Of note,
her AF did not recur until 3-year follow up, and her PACs were
o10 beats/day in repeated Holter electrocardiograms (ECGs). We
did not ablate the distal parts of the PVs. We had some other
patients who had frequent PACs just after AF termination, and we
needed to perform additional ablation to eliminate the PACs just
around the areas previously ablated to terminate AF; we did not
need to ablate the distal portions of the PVs. Thus, the distal
portions of PVs may not be only the main foci of PACs.
4.2. With PLSVC
A PLSVC is the embryological precursor of the ligament of
Marshall, which has been implicated in the initiation and main-
tenance of AF [45–47]. Hsu et al. [48] suggested that the PLSVC is
one of the arrhythmogenic sources of AF and that the PLSVC could
be isolated from both atria in 4 of 5 patients. We previously
reported a case involving a patient with PLSVC that underwentCFAE-guided AF ablation [49]. We have managed 3 PLSVC cases to
date (Fig. 10). Isolation of distal portion of the PLSVC may be
useful when the AF substrate is distally located, although 1 of our
patients’ substrate was located proximal of the CS/PLSVC. We had
ablated the area proximal of the CS/PLSVC without ablating the LA
in that patient until AF was not inducible. Thus, CFAE ablation
appears to be a suitable strategy for AF ablation in patients
with PLSVC.
4.3. After Maze procedure
The majority of anatomical AF ablations are based on the Maze
procedure. Thus, AF ablation for patients with a history of the
Maze procedure may be difﬁcult to perform by an anatomical
approach. We managed a case of CFAE ablation in a patient with a
history of the Maze procedure (Fig. 11). A man with 4-year
persistent AF underwent the Maze procedure combined with
mitral valve plasty 5 years ago. After the operation, his AF had
not recurred for several years, but he subsequently suffered from
1-month persistent AF again. He was quite symptomatic, thus we
underwent CFAE ablation. The posterior wall of the LA had
already been isolated by the Maze procedure, therefore we only
needed to ablate the areas of anterior and septal wall to terminate
AF; the patient’s AF was not inducible after the procedure. He is
still in sinus rhythm.5. Conclusions
CFAE ablation is quite effective for almost all AF patients,
although AF termination does not completely guarantee a good
outcome. CFAE ablation also requires redo procedures in certain
patients. During the redo procedure, we ablate the same areas as
the previous session. The outcome of a single session will be
improved, as the ablation catheter will be improved to allow for
ablation of complete regions to eliminate all of the CFAE areas.
N. Oketani et al. / Journal of Arrhythmia 28 (2012) 311–323 323CFAE ablation is not only our ablation strategy, and we consis-
tently strive to derive new approaches that will yield the best
outcome and to combine anatomical approaches, to minimize the
number of complications, procedure time, and ﬂuoroscopic time.Acknowledgments
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